11,688 Shares in Enliven Therapeutics, Inc. $ELVN Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,688 shares of the company’s stock, valued at approximately $180,000.

Other large investors have also recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in shares of Enliven Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 24,720 shares of the company’s stock valued at $381,000 after acquiring an additional 1,624 shares during the period. XTX Topco Ltd lifted its stake in Enliven Therapeutics by 472.6% in the 4th quarter. XTX Topco Ltd now owns 60,702 shares of the company’s stock valued at $935,000 after purchasing an additional 50,101 shares during the last quarter. Vestal Point Capital LP lifted its stake in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in Enliven Therapeutics by 172.6% in the 4th quarter. Virtus Investment Advisers LLC now owns 15,778 shares of the company’s stock valued at $243,000 after purchasing an additional 9,991 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Enliven Therapeutics by 19.6% during the fourth quarter. Wellington Management Group LLP now owns 129,876 shares of the company’s stock worth $2,000,000 after purchasing an additional 21,316 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ELVN. The Goldman Sachs Group lifted their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Stifel Nicolaus assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 9th. They issued a “buy” rating and a $60.00 price target for the company. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Mizuho raised their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $63.40.

Insider Buying and Selling

In other news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the sale, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Enliven Therapeutics Trading Up 0.5%

Shares of ELVN stock opened at $45.10 on Friday. The firm has a fifty day simple moving average of $41.77 and a two-hundred day simple moving average of $31.41. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $48.53. The firm has a market capitalization of $2.75 billion, a PE ratio of -27.01 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.